MATN3 and cancer: This analysis confirmed that high MATN3 expression served as a predictor of worse disease-specific survival (DSS) and progression-free interval (PFI) in several cancers, including STAD, GBMLGG, COAD, CESC, LIHC, ACC, PCPG, and MESO.